GICS Sector : Healthcare
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases.Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria.The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria.
Travere Therapeutics reported a robust financial performance in Q3 2025, with total revenue reaching $164.9 million, driven by U.S. net product sales of $113.2 million, with FILSPARI contributing $90.9 million. The company's actual EPS came out at $0.28, significantly beating estimates of -$0.31. This strong financial performance was accompanied by continued significant revenue growth, with analysts estimating next year's revenue growth at 37.4%. The company's cash, cash equivalents, and marketable securities totaled approximately $254.5 million as of September 30, 2025.
Publication Date: Nov -25
The company's commercial performance was a key highlight, with FILSPARI's growth in IgA nephropathy driven by sustained commercial excellence, consistent real-world outcomes, and robust long-term data reinforcing its differentiated profile. As Peter Heerma, Chief Commercial Officer, noted, "The third quarter marked another period of strong commercial performance and continued momentum for FILSPARI in IgA nephropathy." FILSPARI net product sales reached approximately $91 million in the third quarter, representing another quarter of strong growth.
With a P/S Ratio of 7.35, the market is pricing in significant revenue growth expectations. Given the company's strong commercial execution and growth drivers, it remains to be seen whether Travere Therapeutics can meet or exceed these expectations. The company's EV/EBITDA ratio stands at -81.64, indicating that the market is pricing in significant future growth. As the company continues to advance its pipeline and prepare for potential approvals and launches, investors will be watching closely to see if the company's growth prospects are realized.
The company is making significant progress in its pipeline, with preparations underway for a potential FDA approval in FSGS and advancements in the manufacturing scale-up of pegtibatinase to support restarting enrollment in the pivotal HARMONY study in 2026. The company's agreement with the PMDA of Japan to initiate 2 Phase III trials for sparsentan in FSGS and Alport syndrome is also a positive development. As Eric Dube, President and Chief Executive Officer, noted, "We've entered the final months of 2025 confident in sustaining FILSPARI's growth in IgAN, executing on a potential approval and launch in FSGS, and advancing our pipeline with focus."
3 Potential Mid-Cap Biotech Buyout Targets In 2026
Dec -03
Travere Therapeutics (NASDAQ:TVTX) Reaches New 52-Week High – Still a Buy?
Nov -30
Travere Therapeutics: Thriving Kidney Franchise Set To Soar On January PDUFA
Nov -26
Why This Fund Trimmed a $161 Million Travere Position After a 100% Rally
Nov -18
Campbell & CO Investment Adviser LLC Makes New $241,000 Investment in Travere Therapeutics, Inc. $TVTX
Nov -18
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov -10
Travere Therapeutics Announces Late-Breaking Data from Phase 3 DUPLEX Study of FILSPARI in FSGS Presented at the American Society of Nephrology (ASN) Kidney Week 2025
Nov -06
Travere Therapeutics to Participate at Upcoming Investor Conferences
Nov -04
Travere Therapeutics' Tiopronin Products' 9.27% growth is driven by increasing adoption in cystinuria treatment, expanded distribution channels, and growing awareness of the product's benefits in reducing kidney stone recurrence. Additionally, strategic partnerships and investments in R&D have enhanced the product's efficacy and patient outcomes, contributing to its rapid growth.
FILSPARI's 11.3% growth is driven by increasing adoption in rare kidney diseases, strong commercial execution, and expanding label indications. Additionally, Travere's strategic partnerships and investments in research and development are expected to fuel further growth.
An oral, selective JAK1 inhibitor for the treatment of rheumatoid arthritis and other inflammatory diseases
A dual endothelin receptor antagonist for the treatment of focal segmental glomerulosclerosis (FSGS) and IgA nephropathy
A novel, orally available, non-absorbed, polymer-based treatment for chronic kidney disease (CKD) patients with metabolic acidosis
Travere Therapeutics, Inc. has a moderate threat of substitutes due to the presence of alternative treatments and therapies for kidney diseases.
Patients and healthcare providers have limited bargaining power due to the specialized nature of Travere Therapeutics, Inc.'s products and services.
Travere Therapeutics, Inc. has a moderate bargaining power of suppliers due to the presence of multiple suppliers for raw materials and services.
The biotechnology industry is highly competitive, and new entrants can easily disrupt the market with innovative products and services.
The biotechnology industry is highly competitive, and Travere Therapeutics, Inc. faces intense rivalry from established players and new entrants.
| Value | |
|---|---|
| Debt Weight | 65.55% |
| Debt Cost | 3.95% |
| Equity Weight | 34.45% |
| Equity Cost | 7.38% |
| WACC | 5.13% |
| Leverage | 190.32% |
Value: 7.4
Growth: 6.1
Quality: 4.8
Yield: 0.0
Momentum: 9.0
Volatility: 2.3
1-Year Total Return ->
Value: 6.2
Growth: 2.3
Quality: 3.8
Yield: 0.0
Momentum: 9.0
Volatility: 2.0
1-Year Total Return ->
Value: 9.8
Growth: 3.6
Quality: 5.1
Yield: 0.0
Momentum: 0.0
Volatility: 3.3
1-Year Total Return ->
Value: 8.8
Growth: 1.2
Quality: 6.9
Yield: 0.0
Momentum: 1.5
Volatility: 0.3
1-Year Total Return ->
Value: 6.6
Growth: 0.9
Quality: 4.0
Yield: 0.0
Momentum: 5.0
Volatility: 0.7
1-Year Total Return ->
Value: 6.4
Growth: 4.7
Quality: 3.4
Yield: 0.0
Momentum: 0.5
Volatility: 0.0
1-Year Total Return ->